

Jean-Louis Montastruc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/641870/publications.pdf>

Version: 2024-02-01

163
papers

3,980
citations

126907

33
h-index

168389

53
g-index

188
all docs

188
docs citations

188
times ranked

4311
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of COVID-19 vaccines: Several modes of expression should be presented in scientific publications. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 218-220.	1.9	7
2	Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database. <i>Journal of Affective Disorders</i> , 2022, 297, 189-193.	4.1	16
3	Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 99-103.	4.0	26
4	Antidepressants are not safe during pregnancy and in women of child-bearing age. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2447-2448.	2.4	2
5	Drug-induced hypohidrosis and anhidrosis: analysis of the WHO pharmacovigilance database 2000-2020. <i>European Journal of Clinical Pharmacology</i> , 2022, , 1.	1.9	1
6	Blood pressure measurements after mRNA-SARS-CoV-2 tozinameran vaccination: a retrospective analysis in a university hospital in France. <i>Journal of Human Hypertension</i> , 2022, 36, 580-581.	2.2	8
7	Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®. <i>Therapie</i> , 2022, 77, 219-227.	1.0	3
8	Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study. <i>Cancer</i> , 2022, 128, 2339-2347.	4.1	2
9	Pharmacovigilance and drug safety: Fair prescribing and clinical research. <i>Therapie</i> , 2022, 77, 261-263.	1.0	48
10	Case Report: A Case of Valproic Acid-Induced Hyperammonemic Encephalopathy Associated With the Initiation of Lithium: A Re-duplicable Finding. <i>Frontiers in Psychiatry</i> , 2022, 13, 875636.	2.6	3
11	NVX-Cov2373 Novavax Covid-19 vaccine: A further analysis of its efficacy using multiple modes of expression. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 1125-1127.	1.9	8
12	Can tramadol really induce hyponatraemia? A pharmacovigilance study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 683-686.	2.4	5
13	Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial. <i>Drug Safety</i> , 2021, 44, 223-233.	3.2	7
14	Towards personalized pharmacology: Antipsychotics and schizophrenia. <i>Therapie</i> , 2021, 76, 137-147.	1.0	3
15	Trends in new prescription of gabapentinoids and of coprescription with opioids in the 4 nations of the UK, 1993-2017. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3349-3353.	2.4	10
16	Cardiovascular adverse effects of anti-IL-5/IL-5R α therapies: A real-world study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1411-1413.	3.8	1
17	Tramadol-induced hypoglycemia: A pharmacovigilance study. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 933-936.	1.9	5
18	Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4334-4340.	2.4	38

#	ARTICLE	IF	CITATIONS
19	Drugs and Dupuytren's disease: a pharmacovigilance study in VigiBase®. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1587-1588.	1.9	0
20	Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective caseâ€“noncase study. <i>Kidney International</i> , 2021, 99, 1235-1236.	5.2	19
21	Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. <i>Clinical Microbiology and Infection</i> , 2021, 27, 791.e5-791.e8.	6.0	83
22	Diarrhoea with the Angiotensin Receptor Neprilysin Inhibitor sacubitril+valsartan: a pharmacovigilance study. <i>Fundamental and Clinical Pharmacology</i> , 2021, , .	1.9	3
23	COVID-19 vaccines: A perspective from social pharmacology. <i>Therapie</i> , 2021, 76, 311-315.	1.0	12
24	Î²-adrenoceptor antagonists and nightmares: A pharmacoepidemiologicalâ€“pharmacodynamic study. <i>Journal of Psychopharmacology</i> , 2021, 35, 1441-1448.	4.0	10
25	Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1937-1938.	1.9	9
26	Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopenia: A missed opportunity for a rapid return of experience. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100889.	1.4	11
27	1921â€“2021, from insulin to new hypoglycaemic drugs: 100 years of pharmacological research in diabetes mellitus. <i>Therapie</i> , 2021, 76, 517-521.	1.0	0
28	Diarrhea and angiotensin II receptor blockers: Is there any difference between the different drugs?. <i>Fundamental and Clinical Pharmacology</i> , 2021, , .	1.9	3
29	Splenic Infarction in a Narcoleptic Patient Treated With Methylphenidate, Venlafaxine, and Pitolisant. <i>Annals of Pharmacotherapy</i> , 2020, 54, 189-190.	1.9	1
30	Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiologic Study. <i>Movement Disorders</i> , 2020, 35, 176-180.	3.9	7
31	Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1-5.	3.5	12
32	Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. <i>Rheumatology</i> , 2020, 59, 2360-2367.	1.9	41
33	Authorsâ€™ Reply to Yu et al.: â€œLevothyroxine® New and Old Formulations: Are They Switchable for Millions of Patients?â€• <i>Clinical Pharmacokinetics</i> , 2020, 59, 283-285.	3.5	1
34	Authorsâ€™ Reply to Nicolas: â€œWhy Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?â€• <i>Clinical Pharmacokinetics</i> , 2020, 59, 277-279.	3.5	0
35	Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 55-59.	2.2	14
36	Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 13-14.	11.4	11

#	ARTICLE	IF	CITATIONS
37	Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study. <i>Drug Safety</i> , 2020, 43, 1315-1322.	3.2	33
38	Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2835-2836.	4.4	59
39	Amiodarone and Parkinsonism: a pharmacovigilance study. <i>Fundamental and Clinical Pharmacology</i> , 2020, 35, 781-784.	1.9	3
40	Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France. <i>Therapie</i> , 2020, 75, 381-384.	1.0	22
41	A New Drugâ€“Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study. <i>Drug Safety</i> , 2020, 43, 657-660.	3.2	10
42	Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1321-1327.	1.9	7
43	Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in VigibaseÂ®. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1479-1480.	1.9	9
44	Fluoroquinolone-Induced Photosensitivity: A Chemical Fragment-Based Approach by a Case/Non-case Study in VigiBaseÂ®. <i>Drug Safety</i> , 2020, 43, 561-566.	3.2	7
45	The Cost of Potentially Inappropriate Medications in Nursing Homes in West Occitanie. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 39.	1.6	7
46	Adverse drug reactions in infants, children and adolescents exposed to antidepressants: a French pharmacovigilance study. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1591-1599.	1.9	6
47	Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 518-520.	1.9	5
48	Reply to: Comment on â€œParkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiological Studyâ€•. <i>Movement Disorders</i> , 2020, 35, 376-377.	3.9	0
49	QT prolongation and vortioxetine: a post-marketing study and comparison with other serotonin reuptake inhibitors. <i>Psychopharmacology</i> , 2020, 237, 1245-1247.	3.1	5
50	Are potentially inappropriate and anticholinergic medications being prescribed for institutionalized elderly subjects?. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 743-748.	1.9	7
51	Interest of a general practitioner pharmacovigilance network to provide drug information: A comparative study in France. <i>Therapie</i> , 2020, 75, 617-622.	1.0	2
52	Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 125-126.	1.9	10
53	POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. <i>Drug Safety</i> , 2019, 42, 45-54.	3.2	10
54	Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3â€“year analysis of the multidomain Alzheimer preventive trial (MAPT) study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 71-99.	2.4	18

#	ARTICLE	IF	CITATIONS
55	Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase^{Â®}. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 108-112.	1.9	4
56	Breast cancer and spironolactone: an observational postmarketing study. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1593-1598.	1.9	3
57	Are lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 695-702.	1.9	1
58	Authors' Reply to Lechat et al.: "Levothyrox ^{Â®} New and Old Formulations: Are they Switchable for Millions of Patients?" <i>Clinical Pharmacokinetics</i> , 2019, 58, 1353-1354.	3.5	6
59	Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1631-1644.	1.9	19
60	Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1053-1058.	3.4	13
61	Trends of atropinic (anticholinergic) exposure in the elderly: a 10-year analysis in the French EGB database. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 471-478.	1.9	6
62	Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. <i>JAMA Psychiatry</i> , 2019, 76, 409.	11.0	175
63	Authors' Reply to Trechot: "Comment on Levothyrox ^{Â®} New and Old Formulations: Are they Switchable for Millions of Patients?" <i>Clinical Pharmacokinetics</i> , 2019, 58, 979-980.	3.5	0
64	Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox ^{Â®} New and Old Formulations: Are they Switchable for Millions of Patients?" <i>Clinical Pharmacokinetics</i> , 2019, 58, 973-975.	3.5	2
65	Authors' Reply to Coste et al.: "Levothyrox ^{Â®} New and Old Formulations: Are they Switchable for Millions of Patients?" <i>Clinical Pharmacokinetics</i> , 2019, 58, 967-968.	3.5	2
66	Authors' Reply to Nicolas: "Levothyrox ^{Â®} New and Old Formulations: Are they Switchable for Millions of Patients?" <i>Clinical Pharmacokinetics</i> , 2019, 58, 961-963.	3.5	0
67	Non-steroidal anti-inflammatory drug prescriptions from the 6 th month of pregnancy: impact of advice from health authorities. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 581-588.	1.9	6
68	Levothyrox ^{Â®} New and Old Formulations: Are they Switchable for Millions of Patients?. <i>Clinical Pharmacokinetics</i> , 2019, 58, 827-833.	3.5	34
69	Does spontaneous adverse drug reactions reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre. <i>Therapie</i> , 2019, 74, 521-525.	1.0	7
70	Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. <i>Therapie</i> , 2019, 74, 209-214.	1.0	10
71	Tamoxifen administration and the risk of Parkinsonism. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 135-136.	1.9	0
72	What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase ^{Â®} . <i>Journal of General Internal Medicine</i> , 2019, 34, 502-503.	2.6	19

#	ARTICLE	IF	CITATIONS
73	Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 314-326.	1.9	1
74	What is pharmacoepidemiology? Definition, methods, interest and clinical applications. <i>Therapie</i> , 2019, 74, 169-174.	1.0	57
75	Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database: Trends and Specific Signals from a Disproportionality Analysis. <i>Drug Safety</i> , 2019, 42, 671-682.	3.2	16
76	Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. <i>Rheumatology</i> , 2019, 58, 683-691.	1.9	38
77	Pharmacoepidemiology, the new paradigm of drug evaluation. <i>Therapie</i> , 2019, 74, 167-168.	1.0	5
78	Tintin in the Land of Drugs: A pharmacological, pharmacovigilance approach. <i>Therapie</i> , 2019, 74, 445-447.	1.0	1
79	Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 450-458.	1.9	6
80	Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 983-984.	1.9	6
81	Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 436-449.	1.9	10
82	Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction. <i>Health Policy</i> , 2018, 122, 237-242.	3.0	11
83	Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting. <i>Drug Safety</i> , 2018, 41, 511-514.	3.2	34
84	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. <i>Chest</i> , 2018, 154, 136-147.	0.8	18
85	Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 174.	1.6	18
86	Atropinic (anticholinergic) burden in antipsychotic-treated patients. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 114-119.	1.9	14
87	Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database. <i>Paediatric Drugs</i> , 2018, 20, 81-87.	3.1	6
88	Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2149.	7.4	90
89	Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 363, k4880.	2.3	33
90	Pregnancy outcomes in women exposed to cancer chemotherapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1302-1308.	1.9	9

#	ARTICLE	IF	CITATIONS
91	Tamoxifen and the risk of Parkinsonism: a case/non-case study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1181-1184.	1.9	9
92	Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2373-2383.	2.4	20
93	Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiologicalâ€“Pharmacodynamic Study in VigiBaseÂ®. <i>Drug Safety</i> , 2018, 41, 1087-1096.	3.2	18
94	Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBaseÂ®. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1673-1674.	1.9	2
95	Neurological and digestive bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists: The differences do not stop there! A pharmacovigilance study. <i>Pharmacological Research</i> , 2017, 118, 119-120.	7.1	2
96	Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1544-1555.	2.4	30
97	Drug-induced panic attacks: Analysis of cases registered in the French pharmacovigilance database. <i>Journal of Psychiatric Research</i> , 2017, 90, 60-66.	3.1	10
98	Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinsonâ€™s disease. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 99-103.	1.9	11
99	Can drugs induce or aggravate sleep apneas? A caseâ€“noncase study in VigiBase^{Â®}, the <sc>WHO</sc> pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 359-366.	1.9	17
100	Statins and diabetes: is there any difference between the different statins?. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1296-1297.	1.9	7
101	A comparative study of QT prolongation with serotonin reuptake inhibitors. <i>Psychopharmacology</i> , 2017, 234, 3075-3081.	3.1	41
102	Concomitant medications and obstructive sleep apnoea. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2315-2316.	2.4	2
103	Duloxetine and gingival bleeding: a case-report and reviews of the French and World PharmacoVigilance Databases and literature. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1197-1198.	1.9	1
104	An original pharmacoepidemiologicalâ€“pharmacodynamic method: application to antipsychoticâ€“induced movement disorders. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 612-622.	2.4	29
105	Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 162-171.	1.9	14
106	Atropinic burden of drugs during pregnancy and psychological development of children: a cohort study in the EFEMERIS database. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 478-486.	2.4	6
107	Pharmacovigilance: The new challenges. <i>Therapie</i> , 2016, 71, 121-122.	1.0	4
108	Pharmacoepidemiology and its input to pharmacovigilance. <i>Therapie</i> , 2016, 71, 211-216.	1.0	31

#	ARTICLE	IF	CITATIONS
109	Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study. <i>Drug Safety</i> , 2016, 39, 1189-1195.	3.2	33
110	Risk of infections during the first year of life after in utero exposure to drugs acting on immunity: A population-based cohort study. <i>Pharmacological Research</i> , 2016, 113, 557-562.	7.1	11
111	Atropinic (Anticholinergic) Burden in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 632-636.	3.9	23
112	Mania associated with ranitidine: a case report and review of literature. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 294-296.	1.9	7
113	Pharmacovigilance, risks and adverse effects of self-medication. <i>Therapie</i> , 2016, 71, 257-262.	1.0	47
114	Comment on: "Drug-Induced Hyperglycaemia and Diabetes". <i>Drug Safety</i> , 2016, 39, 465-466.	3.2	1
115	Quelle Pharmacovigilance pour les vaccins ?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2016, 200, 241-250.	0.0	0
116	Drugs and Sleep Apneas? A review of the French Pharmacovigilance database. <i>Therapie</i> , 2015, 70, 347-350.	1.0	5
117	Adverse drug reactions to self-medication: a study in a pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 517-520.	1.9	39
118	Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French Pharmacovigilance Database. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 891-895.	1.9	10
119	Searching for a Polypharmacy Threshold Associated With Frailty. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 259-261.	2.5	44
120	Exposure to Atropinic Drugs and Frailty Status. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 253-257.	2.5	47
121	Tramadol Use and the Risk of Hospitalization for Hypoglycemia in Patients With Noncancer Pain. <i>JAMA Internal Medicine</i> , 2015, 175, 186.	5.1	86
122	Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA). <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1283-1284.	1.9	2
123	Role of serotonin 5-HT _{2C} and histamine H ₁ receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in Vigibase. <i>European Neuropsychopharmacology</i> , 2015, 25, 1556-1565.	0.7	51
124	Tramadol for Noncancer Pain and the Risk of Hyponatremia. <i>American Journal of Medicine</i> , 2015, 128, 418-425.e5.	1.5	26
125	Qu'est-ce que la pharmacopidmiologie?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2015, 199, 263-273.	0.0	1
126	Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. <i>Rheumatology</i> , 2014, 53, 1864-1871.	1.9	47

#	ARTICLE	IF	CITATIONS
127	Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 230-235.	1.9	36
128	Hepatotoxicity Related to Agomelatine and Other New Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 327-330.	1.4	29
129	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 351-360.	2.4	35
130	Atropinic burden of prescription forms in France: a study in community pharmacies in 2013. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1147-1148.	1.9	10
131	Potentially inappropriate medications and adverse drug reactions in the elderly: a study in a PharmacoVigilance database. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1123-1127.	1.9	22
132	Online Reporting of Adverse Drug Reactions: A Study from a French Regional Pharmacovigilance Center. <i>Therapie</i> , 2014, 69, 395-400.	1.0	24
133	Acute Coronary Syndrome After Nasal Spray of Oxymetazoline. <i>Chest</i> , 2014, 146, e214-e215.	0.8	15
134	Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1589-1597.	1.9	68
135	Potentially inappropriate medications in the elderly in France: a study in community pharmacies in 2011-2012. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 741-742.	1.9	4
136	Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. <i>Acta Diabetologica</i> , 2013, 51, 491-7.	2.5	55
137	Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 885-888.	1.9	24
138	Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 547-548.	2.4	13
139	First French Experience of ADR Reporting by Patients After a Mass Immunization Campaign with Influenza A (H1N1) Pandemic Vaccines. <i>Drug Safety</i> , 2012, 35, 845-854.	3.2	31
140	Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1289-1294.	1.9	30
141	Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1533-1540.	1.9	40
142	The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotonergic reuptake inhibitors in France. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 767-775.	1.9	34
143	Drug Prescribing Before and During Pregnancy in South West France. <i>Drug Safety</i> , 2011, 34, 595-604.	3.2	29
144	Pulmonary Arterial Hypertension and Benfluorex: 5 Case Reports. <i>Therapie</i> , 2011, 66, 135-138.	1.0	8

#	ARTICLE	IF	CITATIONS
145	Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 905-908.	2.4	309
146	Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 649-651.	1.9	12
147	Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France. <i>Movement Disorders</i> , 2011, 26, 2226-2231.	3.9	122
148	Risque hémorragique et syndromes coronariens aigus chez les sujets âgés. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2011, 195, 1981-1987.	0.0	0
149	Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1256-1262.	1.9	107
150	Anticholinergics, antimuscarinics or atropinics? About the words in pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 561-562.	2.4	10
151	What do pregnant women know about non-steroidal anti-inflammatory drugs?. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 1034-1038.	1.9	31
152	Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol). <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 422-426.	2.4	31
153	Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 243-249.	1.9	21
154	The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 808-812.	1.9	68
155	Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. <i>Joint Bone Spine</i> , 2006, 73, 629-632.	1.6	90
156	Risk of Serious Extrapyrarnidal Symptoms in Patients With Parkinson's Disease Receiving Antidepressant Drugs: A Pharmacoepidemiologic Study Comparing Serotonin Reuptake Inhibitors and Other Antidepressant Drugs. <i>Clinical Neuropharmacology</i> , 2003, 26, 142-145.	0.7	51
157	Orthostatic Hypotension in Patients with Parkinson's Disease. <i>Drugs and Aging</i> , 2001, 18, 495-505.	2.7	115
158	Fluoxetine-induced pressor response in freely moving rats: a role for vasopressin and sympathetic tone. <i>Fundamental and Clinical Pharmacology</i> , 2000, 14, 443-451.	1.9	20
159	Lack of autonomic nervous dysfunction in progressive supranuclear palsy, a study of blood pressure variability. <i>Clinical Autonomic Research</i> , 2000, 10, 309-312.	2.5	14
160	Drug Consumption in Workers in France. <i>Journal of Clinical Epidemiology</i> , 1999, 52, 471-478.	5.0	19
161	New Directions in the Drug Treatment of Parkinson's Disease. <i>Drugs and Aging</i> , 1996, 9, 169-184.	2.7	12
162	Antivertigo Medications and Drug-Induced Vertigo. <i>Drugs</i> , 1995, 50, 777-791.	10.9	96

#	ARTICLE	IF	CITATIONS
163	Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Movement Disorders, 1994, 9, 437-440.	3.9	78